FGEN Rasio cepet FibroGen, Inc.

Developing treatments for fibrosis and anemia requires colossal expenditures and strict safety controls. FibroGen, Inc. (FGEN) is currently fighting for survival, shifting its scientific focus following a series of trial failures. The business relies on external contract manufacturing organizations to maintain its focus on research, while the indicator stands at 3.47. This daily price chart below illustrates the price action for FibroGen, Inc. (FGEN).

The quick ratio assesses the ability of FibroGen, Inc. (FGEN) to meet its current obligations using cash and accounts receivable, completely excluding low-liquidity inventories from the calculation. By analyzing this ratio of liquid assets to short-term liabilities, an investor determines the financial stability of FibroGen, Inc. as it implements its therapeutic pipeline expansion strategy and scales licensing agreements with pharmaceutical behemoths.